PDF herunterladen
Homeopathy 2009; 98(03): 169-176
DOI: 10.1016/j.homp.2009.05.001
Original Paper
Copyright © The Faculty of Homeopathy 2009

A review of immunomodulators with reference to Canova®

E. Smit
,
H.M. Oberholzer
,
E. Pretorius
Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Received27. November 2008
revised30. April 2009

accepted05. Mai 2009

Publikationsdatum:
20. Dezember 2017 (online)

    Lizenzen und Reprints

Immunomodulators are substances which modify the immunity of an individual to favour a particular immunological response. The immune response and the function of the immune response regulation process are described, with special reference to cancer and autoimmune disease. Homeopathy and its role in immune regulation are discussed with special reference to Canova®. Canova® is a homeopathic product produced, according to the Hahnemannian homeopathic method, in Brazil. Its role in cancer, bone marrow and haematopoiesis as well as macrophage and monocyte activation is reviewed. Canova® seems to stabilize platelet morphology in human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

The data suggest that the future of immunomodulators and homeopathic products which appear to have an effect on the immune response requires a better understanding of the relative need for immune activation versus immune modulation. Homeopathic products specifically need more attention.

 

  • References

  • 1 Patwardhan B., Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov Today 2005; 10 (07) 495-502.
    CrossrefPubMedGoogle Scholar
  • 2 Levy M.N., Koeppen B.M., Stanton B.A. Nonrespiratory functions of the lung. In: Schmitt W.R., Hall A. Principles of Physiology. 2006. Philadelphia: Mosby, Elsevier; 417-428
    Google Scholar
  • 3 Kierszenbaum A.L. Immune-lymphatic system. In: Ozols I., Hall A. Histology and Cell Biology. An Introduction to Pathology. 2007. Philadelphia, Mosby: Elsevier; 291-322
    Google Scholar
  • 4 Dutta R.C. Peptide immunomodulators versus infection; an analysis. Immunol Lett 2002; 83 (03) 153-161.
    CrossrefPubMedGoogle Scholar
  • 5 Ballas Z.K. Immunomodulators: a brave new world. J Allergy Clin Immunol 2008; 121 (02) 331-333.
    CrossrefPubMedGoogle Scholar
  • 6 Piemonte M., Buchi D. Analysis of IL-2, IFN-γ and TNF-α production, α5β1 integrins and actin filaments distribution in peritoneal mouse macrophages treated with homeopathic medicament. J Submicrosc Cytol Pathol 2002; 34 (03) 255-263.
    PubMedGoogle Scholar
  • 7 Casale T.B., Stokes J.R. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008; 121 (02) 288-296.
    CrossrefPubMedGoogle Scholar
  • 8 Pirofski L., Casadevall A. Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 2006; 9: 489-495.
    CrossrefPubMedGoogle Scholar
  • 9 Abbas A.K., Lichtman A.H. Antigen capture and presentation to lymphocytes. In: Schmitt W.R., Hacker H.N., Bellus M.A. Basic Immunology. Functions and Disorders of the Immune System. 2001. Philadelphia, Pennsylvania, USA: WB Saunders Company; 43-64
    Google Scholar
  • 10 Randolph G.J., Jakubzick C., Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 2008; 20: 52-60.
    CrossrefPubMedGoogle Scholar
  • 11 Peakman M., Vergani D. Cellular immune responses: macrophages, dendritic cells and B lymphocytes. In: Ward J. Basic and Clinical Immunology. 1997. Edinburgh: Churchill Livingstone; 67-80
    Google Scholar
  • 12 Todd I., Spickett G. Antigen recognition. In: Noyes V., Misina M. Immunology (Lecture Notes). 5th edn. 2005. Massachusetts, USA: Blackwell Publishing Ltd; 14-27
    Google Scholar
  • 13 Mahnke K., Bedke T., Enk A.H. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007; 250: 1-13.
    CrossrefPubMedGoogle Scholar
  • 14 Dabbagh K., Lewis D.B. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003; 16: 199-204.
    CrossrefPubMedGoogle Scholar
  • 15 Delneste Y., Beauvillain C., Jeannin P. Innate immunity: structure and function of TLRs. Méd Sci 2007; 23 (01) 67-73.
    PubMedGoogle Scholar
  • 16 Atkinson T.J. Toll-like receptors, transduction effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness?. Int Rev Immunol 2008; 27: 255-281.
    CrossrefPubMedGoogle Scholar
  • 17 Majewska M., Szczepanik M. The role of Toll-like receptors (TLR) in innate and adaptive immune responses and their function in immune response regulation. Postepy Hig Med Dosw 2006; 60: 52-63.
    PubMedGoogle Scholar
  • 18 Berinstein N.L. Enhancing cancer vaccines with immunomodulators. Vaccine 2007; 25: 27-88.
    CrossrefPubMedGoogle Scholar
  • 19 Meyer T., Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008; 17 (07) 1051-1065.
    CrossrefPubMedGoogle Scholar
  • 20 Pollard T.D., Earnshaw W.C. Signalling mechanisms: plasma membrane receptors. In: Schmitt W., Mahon J. Cell Biology. 2004. Philadelphia: Saunders-Elsevier; 427-442
    Google Scholar
  • 21 Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin Exp Immunol 2003; 132: 185-192.
    CrossrefPubMedGoogle Scholar
  • 22 Spelman K., Burns J., Nichols D., Winters N., Ottersberg S., Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev 2006; 11 (02) 128-150.
    PubMedGoogle Scholar
  • 23 Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune disease. Cytokine Growth Factor Rev 2008; 19: 41-52.
    CrossrefPubMedGoogle Scholar
  • 24 Finckh A., Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 2008; 20: 269-275.
    CrossrefPubMedGoogle Scholar
  • 25 Okamoto H., Hoshi D., Kiire A., Yamanaka H., Kamatani N. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets 2008; 7 (01) 53-66.
    CrossrefPubMedGoogle Scholar
  • 26 Kirkwood J.M., Tarhini A.A., Panellini M.C. et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26 (20) 3445-3455.
    CrossrefPubMedGoogle Scholar
  • 27 Brandenburg S., Takahasi T., de la Rosa M. et al. IL-2 induces in vivo suppression by CD4+CD25+Fox3+ regulatory T cells. Eur J Immunol 2008; 38: 1643-1653.
    CrossrefPubMedGoogle Scholar
  • 28 Tsitoura D.C., Tassios Y. Immunomodulation: the future cure for allergic diseases. Ann NY Acad Sci 2006; 1088: 100-115.
    CrossrefPubMedGoogle Scholar
  • 29 <www.nccam.nih.gov>
    PubMed
  • 30 Reichenberg-Ullman J. Transformational homeopathy. The Towshend Letter Group; 2007.
    Google Scholar
  • 31 Jobst K.A. Homeopathy, Hahnemann and the Lancet and 250 years on: a case of the Emperor's new clothes?. J Altern Complement Med 2005; 11 (05) 751-754.
    CrossrefPubMedGoogle Scholar
  • 32 Seligmann I.C., Lima P.D.L., Cardoso P.C.S. et al. The Canova method homeopathic compound is not genotoxic to the in vitro human lymphocytes. Genet Mol Res 2003; 2: 223-228.
    PubMedGoogle Scholar
  • 33 Lopes L., Godoy L.M.F., de Oliveira C.C. et al. Phagocytosis, endosomal/lysosomal system and other cellular aspects of macrophage activation by Canova medication. Micron 2006; 37: 277-287.
    CrossrefPubMedGoogle Scholar
  • 34 Pereira W.K.V., Lonardoni M.V.C., Grespan R., Caparroz-Assef S.M., Cuman R.K.N., Bersani-Amado C.A. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection. J Infect 2005; 51: 157-168.
    CrossrefPubMedGoogle Scholar
  • 35 Takahachi G., Maluf M.L.F., Svidzinkski T.I.E., Dalalio M.M.O., Bersani-Amado C.A., Cuman R.K.N. In vitro and in vivo effects of the Canova medicine on experimental infection with Paracoccidioides brasiliensis in mice. Indian J Pharmacol 2006; 28 (05) 350-354.
    PubMedGoogle Scholar
  • 36 <www.botanical.com>
    PubMed
  • 37 Cummings S., Dana U. Everybody's guide to homeopathic medicines. New York: Jeremy P. Tarcher/Putnam; 1997.
    Google Scholar
  • 38 Kent J.T. Lectures on Materia Medica . Delhi, India: B. Jain Publishers; 1996.
    Google Scholar
  • 39 De Oliveira C.C., De Oliveira S.M., Godoy L.M.F., Gabardo J., De Freitas Buchi D. Canova, a Brazilian medical formulation, alters oxidative metabolism of mice macrophages. J Infect 2006; 52: 420-432.
    CrossrefPubMedGoogle Scholar
  • 40 Sato D., Wal R., de Oliveira C.C. et al. Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a complex homeopathic medication. Homeopathy 2005; 94: 26-32.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Burbano R.R., Leal M.F., da Costa J.B. et al. Lymphocyte proliferation stimulated by activated human macrophages treated with Canova. Homeopathy 2009; 98 (01) 45-48.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 42 Abud A.P.R., Cesar B., Cavazzani L.F.M., de Oliveira C.C., Gabardo J., Buchi D. Activation of bone marrow cells treated with Canova in vitro . Cell Biol Int 2006: 1-9
    PubMedGoogle Scholar
  • 43 Smit E., Pretorius E., Anderson R., Oomen J., Potjo M. Differentiation of human monocytes in vitro following exposure to Canova in the absence of cytokines. Ultrastruct Pathol 2008; 32: 147-152.
    CrossrefPubMedGoogle Scholar
  • 44 Pretorius E., Oberholzer H.M., Smit E. et al. Ultrastructural changes in platelet aggregates of HIV patients: a scanning electron microscopy study. Ultrastruct Pathol 2008; 32: 1-5.
    CrossrefPubMedGoogle Scholar
  • 45 Aleixo D.L., Ferraz F.N., de Melo C.S. et al. Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole. Homeopathy 2008; 97 (02) 59-64.
    Artikel in Thieme ConnectPubMedGoogle Scholar